Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK and PD of GZR33 and GZR101 in Healthy Men
NCT06548932Phase 1Completed
- Sponsor
- Gan & Lee Pharmaceuticals
- Start
- Jun 2022
- Primary completion
- Feb 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GZR33 and insulin aspart in diabetes mellitus (DM) (2 arms), sponsored by Gan & Lee Pharmaceuticals. Primary endpoint: Incidence of adverse events. Started Jun 2022; status: completed.
02
Drugs
GZR33insulin aspart
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on NCT06548932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06548932.